SAN CARLOS, Calif. & LISBON, Portugal--March 7, 2024--CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it will present additional positive Phase 2a...
Liquidia begins testing flu vaccine
Liquidia Technologies has started early clinical testing of its first vaccine developed using nanotechnology.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.